Skip to main contentAI and Advanced
/
GUFICBIO · NSEMarket ticker unavailable · configure an authorised index feed
GU
NSE · Equity shares · Biotechnology & Drugs-5.00 · -1.17%
Gufic BioSciences GUFICBIO
NSE:INR 420.9
BSE:INR 405.25
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for GUFICBIO
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 425.9
Day rangeINR 404.1 — INR 424.45
52-week rangeINR 268 — INR 467.8
Volume1.13 L
Market cap4,046.98
P/E61.62
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)944.01
Net Income (INR Cr)64.21
Rev Growth (5 Year %)14.12
EPS Growth (5 Year %)7
P/E Ratio61.62
Book Value65.69
EPS6.4
Price/BV6.41Computed
Research path: Interpret Gufic BioSciences's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
GUFICBIOGufic BioSciences1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,342.37 | 1,169.36 | 1,092.54 |
| Cash Equivalents | 76.22 | 15.72 | 1.14 |
| Other Liabilities Total | 23.56 | 22.87 | 20.35 |
| Long Term Debt | 105.04 | 128.95 | 153.89 |
| Common Stock Total | 10.03 | 10.03 | 10.03 |
| Other Current Assets Total | 101.8 | 0.21 | 2.91 |
| Total Assets | 1,342.37 | 1,169.36 | 1,092.54 |
| Current Portof LT Debt/Capital Leases | 285.34 | 31.83 | 25.38 |
| Total Equity | 664.95 | 601.08 | 532.56 |
| Long Term Investments | 1.78 | 1.78 | 1.78 |
| Retained Earnings(Accumulated Deficit) | 654.92 | 491.39 | 522.53 |
| Total Common Shares Outstanding | 10.03 | 10.03 | 10.03 |
| Tangible Book Valueper Share Common Eq | 65.69 | 59.31 | 52.55 |
| Total Liabilities | 677.43 | 568.29 | 559.98 |
| Total Debt | 404.75 | 336.19 | 332.92 |
| Cashand Short Term Investments | 76.22 | 29 | 13.46 |
| Total Receivables Net | 299.63 | 377.13 | 382.76 |
| Deferred Income Tax | 16.57 | 7.77 | 2.06 |
| Accounts Receivable-Trade Net | 297.4 | 314.61 | 329.94 |
| Property/Plant/Equipment Total-Net | 507 | 521.46 | 460.33 |
| Minority Interest | 0.04 | 0 | Not available |
| Total Current Liabilities | 517.85 | 387.56 | 372.05 |
| Total Inventory | 324.47 | 216.87 | 200.48 |
| Accounts Payable | 199.03 | 158.75 | 166.27 |
| Other Currentliabilities Total | 33.48 | 42.32 | 37.96 |
| Total Long Term Debt | 119.41 | 150.09 | 165.52 |
| Intangibles Net | 6.16 | 6.34 | 5.62 |
| Other Long Term Assets Total | 24.79 | 11.8 | 10.08 |
| Note Receivable-Long Term | 0.52 | 3.44 | 14.25 |
| Total Current Assets | 802.12 | 624.52 | 600.48 |
| Capital Lease Obligations | 14.37 | 21.14 | 11.63 |
| Accumulated Depreciation Total | Not available | -106.41 | -86.21 |
| Accrued Expenses | Not available | 0.38 | 0.43 |
| Prepaid Expenses | Not available | 1.31 | 0.86 |
| Additional Paid-In Capital | Not available | 99.66 | Not available |
| Property/Plant/Equipment Total-Gross | Not available | 606.06 | 239.48 |
| Short Term Investments | Not available | 13.28 | 12.33 |
| Notes Payable/Short Term Debt | Not available | 154.27 | 142.02 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %45.75
Margins
Operating Margin 5y Avg15.17
Net Profit Margin 5y9.79
Valuation
Price to Sale Ratio4.29
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk39.55
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.87 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 74.03 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 76.43 | — |
| Cipla | INR 1,475 | 1.19 L | 28.01 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.29 | — |
Shareholding
Ownership
- Promoter
- 72.50%
- FII
- 0.47%
- MF
- 3.43%
- Other
- 23.60%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Gufic BioSciences Ltd Upgraded to Hold as Financial and Technical Trends Improve - Markets MojoMarket news · 4 Jun 2026, 9:20 am
Gufic BioSciences Ltd Upgraded to Hold as Financial and Technical Trends Improve Markets Mojo
Gufic BioSciences Ltd Shows Technical Momentum Shift Amid Mixed Indicator Signals - Markets MojoMarket news · 4 Jun 2026, 8:15 am
Gufic BioSciences Ltd Shows Technical Momentum Shift Amid Mixed Indicator Signals Markets Mojo
Gufic Bio Consolidated March 2026 Net Sales at Rs 251.82 crore, up 22.83% Y-o-Y - Moneycontrol.comMarket news · 3 Jun 2026, 12:55 pm
Gufic Bio Consolidated March 2026 Net Sales at Rs 251.82 crore, up 22.83% Y-o-Y Moneycontrol.com
Gufic Biosciences Q1FY27 Concall: Margins, CapEx & Revenue Guidance - scanx.tradeMarket news · 3 Jun 2026, 10:46 am
Gufic Biosciences Q1FY27 Concall: Margins, CapEx & Revenue Guidance scanx.trade
Gufic BioSciences Ltd Shows Mixed Technical Signals Amid Sideways Momentum Shift - Markets MojoMarket news · 3 Jun 2026, 8:24 am
Gufic BioSciences Ltd Shows Mixed Technical Signals Amid Sideways Momentum Shift Markets Mojo
Gufic BioSciences Q4 FY26: Strong Profit Surge Masks Valuation Concerns - Markets MojoMarket news · 3 Jun 2026, 2:01 am
Gufic BioSciences Q4 FY26: Strong Profit Surge Masks Valuation Concerns Markets Mojo
Corporate actions
Events
- dividendRs.0.1000 per share(10%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.0.1000 per share(10%)Final Dividend
- board MeetingsQuarterly Results
- board MeetingsAudited Results & Final Dividend
Rusaka Markets Community
Discussion and sentiment for Gufic BioSciences
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Gufic Biosciences Limited is an India-based company, which is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Company operates in the pharmaceutical segment. It has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole and Everolimus. Its Gufic Stridden includes Irvical and Eve.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- GUFICBIO
- BSE Code
- 509079
Questions
Stock FAQ
What is the symbol and ISIN of Gufic BioSciences?
Gufic BioSciences has the symbol GUFICBIO and ISIN - INE742B01025.
What is the current price of Gufic BioSciences?
Gufic BioSciences is currently trading at INR 420.90.
What are the year high and year low of Gufic BioSciences?
Gufic BioSciences has a year high of INR 467.80 and a year low of INR 268.00.
What is the market capitalization of Gufic BioSciences?
Gufic BioSciences has a market capitalization of INR 4,046.98 crore.
What is the P/E ratio of Gufic BioSciences?
Gufic BioSciences has a P/E ratio of 61.62.
What is the dividend yield of Gufic BioSciences?
Gufic BioSciences has a dividend yield of NA.
How is the financial performance of Gufic BioSciences based on revenue, net income, and EPS?
Gufic BioSciences has revenue of INR 944.01 crore, net income of INR 64.21 crore, and EPS of NA.
What is the book value of Gufic BioSciences?
Gufic BioSciences has a book value of INR 65.69.
What is the debt-to-equity ratio of Gufic BioSciences?
Gufic BioSciences has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Gufic BioSciences?
Gufic BioSciences has a price-to-book ratio of 6.41 and a price-to-sales ratio of 4.29.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.